
Pfizer, Inc.: updates and filings
Price
$28.18
November 18, 2026Market cap $160B
What Ploutos Investor adds for Pfizer
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Nov 3, 2026Officer or director changeForm8-K
- Nov 3, 2026Quarterly reportfor the period to Sep 27, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Aug 31, 2026FilingFormN-PX
- Aug 13, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Aug 4, 2026Quarterly reportfor the period to Jun 28, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jun 18, 2026Regulation FD disclosureForm8-K
- Jun 18, 2026Officer or director changeForm8-K
- Jun 16, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- Jun 16, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- May 12, 2026Its own holdings as an investment manager (13F)Form13F-HR
- May 5, 2026Shares registered for employeesFormS-8
- May 5, 2026Quarterly reportfor the period to Mar 29, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 27, 2026Shareholder voteForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 12, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 12, 2026Additional annual meeting materialFormDEFA14A
- Mar 12, 2026Annual meeting proxy statementFormDEF 14A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 12, 2026Its own holdings as an investment manager (13F)Form13F-HR
- Feb 3, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Nov 3, 2026 | 8-K | Officer or director change | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 27, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Aug 31, 2026 | N-PX | Filing | Document |
| Aug 13, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 28, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jun 18, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Officer or director change | Document |
| Jun 16, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| Jun 16, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| May 12, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| May 5, 2026 | S-8 | Shares registered for employees | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 29, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 27, 2026 | 8-K | Shareholder vote | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 12, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 12, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 12, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 12, 2026 | 13F-HR | Its own holdings as an investment manager (13F) | Document |
| Feb 3, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Mar 18, 1994: every report, 8-K, meeting and letter. Of its other filings (1,271 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 68.
The full analysis
What do Pfizer's filings show?
The filings are where every one of Pfizer's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.